申请人:UCB PHARMA SA
公开号:WO2009071890A1
公开(公告)日:2009-06-11
A series of fused tricyclic thiazole and thiophene derivatives which are substituted in the 2-position of the thiazole or thiophene ring by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
一系列融合的三环噻唑和噻吩衍生物,其在噻唑或噻吩环的2位被一个可选择取代的吗啡啉-4-基团取代,是选择性PI3激酶酶抑制剂,在医学上具有益处,例如在治疗炎症性、自身免疫性、心血管、神经退行性、代谢性、肿瘤学、疼痛性或眼科疾病方面。